XFOR
X4 Pharmaceuticals, Inc
-0.09 (-2.71%)3.42USD201K成交股數339M市值2.7本益比(近四季)21.4股價營收比+346.3%營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 8.8M-69% | 2.7M+89% | 1.8M+215% | 2.0M+250% | 28.8M | 1.4M | 560K | 563K | 0 | 0 | 0 | – |
| 營業成本 | 1.6M | 598K | 351K | 326K | 4.7M | 302K | 227K | 268K | 0 | 0 | 0 | – |
| 毛利 | 7.2M-70% | 2.1M+86% | 1.4M+325% | 1.6M+458% | 24.1M | 1.1M | 333K | 295K | 0 | 0 | 0 | – |
| 毛利率 | 81.6% | 77.9% | 80.1% | 83.5% | 83.6% | 78.9% | 59.5% | 52.4% | – | – | – | – |
| 研發費用 | 15.1M | 15.5M | 17.3M | 18.4M | 18.5M | 21.7M | 19.2M | 20.9M | 19.9M | 19.1M | 15.6M | 22.1M |
| 銷售管理費用 | 8.5M | 7.0M | 11.6M | 9.5M | 15.0M | 15.1M | 15.7M | 13.3M | 17.4M | 8.1M | 10.2M | 7.2M |
| 營業利益 | −16.4M+74% | −20.3M-43% | −27.5M-20% | −26.2M-137% | −9.4M-75% | −35.7M+31% | −34.5M+34% | 71.1M-343% | −37.3M | −27.2M | −25.8M | −29.3M |
| 營業利益率 | -186.1% | -749.9% | -1,558.6% | -1,329.5% | -32.8% | -2,490.6% | -6,160.7% | 12,629.3% | – | – | – | – |
| 稅後淨利 | −16.2M-5829% | −20.2M-49% | −29.8M-19% | −25.7M-128% | 282K-101% | −39.8M+1628% | −36.7M-34% | 90.8M-478% | −51.8M | −2.3M | −55.7M | −24.0M |
| 淨利率 | -183.5% | -747.5% | -1,689.2% | -1,304.7% | 1.0% | -2,776.9% | -6,552.9% | 16,133.7% | – | – | – | – |
| 稀釋 EPS | -0.13-425% | -0.16-97% | -0.69-87% | -3.47-126% | 0.04-101% | -5.91+59000% | -5.48+1561% | 13.57-8581% | -7.77 | -0.01 | -0.33 | -0.16 |
| 稀釋股數 | 126M | 126M | 43.3M | 7.4M | 6.9M | 6.7M | 6.7M | 6.7M | 6.7M | 197M | 169M | 146M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 195M | 217M | 69.6M | 39.2M | 40.3M | 55.7M | 97.4M | 147M | 60.5M | 132M | 136M | 93.4M |
| 應收帳款 | 2.0M | 1.1M | 891K | 1.1M | 509K | 1.1M | 0 | 0 | – | – | – | – |
| 存貨 | – | – | – | – | – | 2.8M | – | – | – | – | – | – |
| 總資產 | 253M | 270M | 164M | 105M | 130M | 146M | 178M | 211M | 112M | 173M | 173M | 124M |
| 有息負債 | 75.0M | 75.0M | 75.0M | 75.0M | 75.0M | 75.0M | 75.0M | 75.0M | 55.0M | 55.0M | 32.5M | 32.5M |
| 總負債 | 97.6M | 102M | 102M | 101M | 107M | 124M | 119M | 116M | 111M | 106M | 106M | 72.7M |
| 股東權益 | 155M | 168M | 61.6M | 4.0M | 22.9M | 22.1M | 59.6M | 94.5M | 1.0M | 67.6M | 67.5M | 51.7M |
| 負債比 | 38.6% | 37.7% | 62.3% | 96.2% | 82.4% | 84.9% | 66.5% | 55.2% | 99.1% | 61.0% | 61.1% | 58.5% |
| 淨現金(現金 − 有息負債) | 120M | 142M | −5.4M | −35.8M | −34.7M | −19.3M | 22.4M | 72.2M | 5.5M | 76.6M | 104M | 60.9M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −19.6M | – | – | −12.4M-63% | – | – | −63.9M+141% | −33.6M | −68.8M | −47.9M | −26.5M |
| 資本支出 | – | – | – | – | 0 | – | – | – | 59K | – | – | 9K |
| 自由現金流 | – | – | – | – | −12.4M-63% | – | – | – | −33.7M | – | – | −26.5M |
| 折舊攤銷 | – | 223K | – | – | 476K | – | – | – | 62K | – | – | 127K |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | 443K |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | -42.9% | – | – | – | – | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 35.1M
| Reportable | 35.1M | 100.0% | +1273.2% |
|---|
主要客戶2025 年度 · 35.1M
| United Kingdom Special Pharmacy Customer | 28.6M | 81.5% | – |
|---|---|---|---|
| U.S.Specialty Pharmacy Customer | 6.5M | 18.5% | +150.0% |
產品／服務2025 年度 · 35.1M
| License And Other Revenue | 28.6M | 81.4% | – |
|---|---|---|---|
| 產品 | 6.5M | 18.6% | +155.1% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 35.1M | +1273.2% | −79.2M | -225.6% | -1.87 | −85.6M |
| FY2024 | 2.6M | – | −37.5M | -1,464.6% | -5.59 | −131M |
| FY2023 | 0 | – | −101M | –% | -17.07 | −96.6M |
| FY2022 | 0 | – | −93.9M | –% | -1.52 | −77.2M |
| FY2021 | 0 | -100.0% | −88.7M | –% | -3.99 | −71.5M |
| FY2020 | 3.0M | – | −62.1M | -2,071.0% | -3.09 | −60.2M |
| FY2019 | 0 | – | −52.8M | –% | -4.63 | −48.2M |
| FY2018 | 0 | – | −33.3M | –% | -79.15 | −25.4M |